Salix Pharma will co-promote Doptelet for thrombocytopenia in the US with Dova Pharma.

Dova Pharmaceuticals, Inc. and Salix Pharmaceuticals and its parent company, Bausch Health Companies Inc. announced that they have entered into an exclusive agreement to co-promote Dova�s Doptelet (avatrombopag) in the United States . The FDA approved Doptelet on 21 May 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. Doptelet represents the first thrombopoietin (TPO) receptor agonist approved in the United States for this indication.

As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote Doptelet to gastroenterology healthcare professionals. The Salix sales force will begin selling Doptelet in mid-October 2018. Dova will continue its commercial efforts targeting primarily hepatologists and interventional radiologists and certain other specialties. Pursuant to the agreement, Dova will pay Salix a quarterly fee based on net sales (as defined in the agreement) of Doptelet prescribed by gastroenterologists in the U.S.